Other
Bariatric Surgery
0
Pipeline Programs↗
39
Active Trials↗
3
Companies Involved↗
Bariatric Surgery is an early-stage landscape with 0 programs across 3 companies. The most active players are Aardvark Therapeutics, Inc., Takeda, AstraZeneca.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
121
clinical trials
Completed51 · 42%
Recruiting28 · 23%
Unknown status23 · 19%
Not yet recruiting6 · 5%
Withdrawn4 · 3%
Terminated3 · 2%
Other6 · 5%
Clinical Trials
Trial Activity
121 trials
2024 Tirzepatide-Bariatric Surgery
Recruiting·—·Phase 4·NCT06721507·50 enrolled
Bariatric Surgery vs. Semaglutide vs. Tirzepatide
Recruiting·—·Phase 4·NCT06803888·125 enrolled
Page 1 of 9
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)